New registry to monitor Belzutifan's Real-World impact on rare VHL tumors
NCT ID NCT07554508
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will follow 100 adults with von Hippel-Lindau (VHL) disease who choose to take belzutifan. Researchers will track how well the drug shrinks tumors, its side effects, and its impact on quality of life and healthcare costs. The goal is to better understand the drug's real-world benefits and risks for this rare genetic condition.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VHL - VON HIPPEL-LINDAU SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Prince of Wales Hospital
Shatin, Hong Kong
More trials for these conditions
Other studies related to the condition(s) this trial covers.